Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial 31% objective response rate seen in trial patients, and an estimated 85% of responses … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science
Tagged advanced basal cell carcinoma, Alexander Stratigos M.D., Andreas Sygros Hospital, basal cell carcinoma, BCC, biopharmaceutical, cemiplimab, ESMO Virtual Congress 2020, European Society for Medical Oncology, hedgehog inhibitor, HHI therapy, inhibitor, Libtayo®, Regeneron, Sanofi, University of Athens Medical School
Erivedge is a new medicine that helps people with a disfiguring and potentially life-threatening form of skin cancer 19-7-2013 — /europawire.eu/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional approval to Erivedge (vismodegib) … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
